Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma.

ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer.

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GXP-1 is under development for the treatment of psoriasis, rheumatoid arthritis, inflammation of the colon, stroke, premature labor (tocolysis) and transplantation rejection. It is administered ...

GMA-106 is under development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). The drug candidate is being developed based on Bibody platform. It acts by ...

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...